Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Ampyra (dalfampridine) medication guide
From "Wheelchair Circuit" to "Wheelchair Assessment Instrument for People with Multiple Sclerosis": Reliability and Validity Analysis of a Test to Assess Driving Skills in Manual Wheelchair Users With Multiple Sclerosis.
Don't stress about it!: Is stress management a disease-modifying therapy for multiple sclerosis?
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis
Energy Cost of Walking and Its Association With Gait Parameters, Daily Activity, and Fatigue in Persons With Mild Multiple Sclerosis.
Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
Regression-Based Norms Improve the Sensitivity of the National MS Society Consensus Neuropsychological Battery for Pediatric Multiple Sclerosis (NBPMS).
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Imaging In The Cell
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
Mutations affecting segment number and polarity in Drosophila.
Nerve Conduction Velocity Is Regulated by the Inositol Polyphosphate-4-Phosphatase II Gene.
Reproductive issues in women with multiple sclerosis: ethical considerations.
Unraveling the secrets of white matter - Bridging the gap between cellular, animal and human imaging studies.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Correlates of Executive Functions in Multiple Sclerosis Based on Structural and Functional MR Imaging: Insights from a Multicenter Study.
Association mapping of disease loci, by use of a pooled DNA genomic screen.
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.
Pages
« first
‹ previous
…
154
155
156
157
158
159
160
161
162
…
next ›
last »